The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $5.16

Today's change-0.14 -2.64%
Updated June 29 11:01 AM -4GMT. Delayed by at least 15 minutes.
 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $5.16

Today's change-0.14 -2.64%
Updated June 29 11:01 AM -4GMT. Delayed by at least 15 minutes.

Osiris Therapeutics Inc crosses below 50-day moving average

Osiris Therapeutics Inc is sharply lower today, dropping (U.S.)$0.14 or 2.64% to (U.S.)$5.16 and crossing below its 50-day moving average. Over the last five days, shares have lost 0.77% and are down 50.29% for the last year to date. This security has underperformed the S&P 500 by 72.72% during the last year.

Key company metrics

  • Open(U.S.) $5.34
  • Previous close(U.S.) $5.30
  • High(U.S.) $5.34
  • Low(U.S.) $5.06
  • Bid / Ask(U.S.) $5.15 / (U.S.) $5.19
  • YTD % change-50.29%
  • Volume52,927
  • Average volume (10-day)145,249
  • Average volume (1-month)141,819
  • Average volume (3-month)201,459
  • 52-week range(U.S.) $3.55 to (U.S.) $23.67
  • Beta0.73
  • Trailing P/E104.75×
  • P/E 1 year forward66.25×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.05
Updated June 29 11:01 AM -4GMT. Delayed by at least 15 minutes.
S&P TSX1.36%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue25242119
Total other revenue--------
Total revenue25242119
Gross profit20191615
Total cost of revenue5554
Total operating expense25221918
Selling / general / administrative17151310
Research & development2224
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total----00
Operating income0221
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-1221
Income after tax-1111
Income tax, total0010
Net income-1111
Total adjustments to net income--------
Net income before extra. items-1111
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1111
Inc. avail. to common incl. extra. items-1111
Diluted net income-1111
Dilution adjustment--000
Diluted weighted average shares34353534
Diluted EPS excluding extraordinary itemsvalue per share-0.020.030.040.03
Dividends per sharevalue per share0.200.000.00--
Diluted normalized EPSvalue per share-0.020.030.040.03